Blood Advances (Jul 2018)

A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms

  • Carolina Martínez-Laperche,
  • Elena Buces,
  • M. Carmen Aguilera-Morillo,
  • Antoni Picornell,
  • Milagros González-Rivera,
  • Rosa Lillo,
  • Nazly Santos,
  • Beatriz Martín-Antonio,
  • Vicent Guillem,
  • José B. Nieto,
  • Marcos González,
  • Rafael de la Cámara,
  • Salut Brunet,
  • Antonio Jiménez-Velasco,
  • Ildefonso Espigado,
  • Carlos Vallejo,
  • Antonia Sampol,
  • José María Bellón,
  • David Serrano,
  • Mi Kwon,
  • Jorge Gayoso,
  • Pascual Balsalobre,
  • Álvaro Urbano-Izpizua,
  • Carlos Solano,
  • David Gallardo,
  • José Luis Díez-Martín,
  • Juan Romo,
  • Ismael Buño

Journal volume & issue
Vol. 2, no. 14
pp. 1719 – 1737

Abstract

Read online

Abstract: Despite considerable advances in our understanding of the pathophysiology of graft-versus-host disease (GVHD), its prediction remains unresolved and depends mainly on clinical data. The aim of this study is to build a predictive model based on clinical variables and cytokine gene polymorphism for predicting acute GVHD (aGVHD) and chronic GVHD (cGVHD) from the analysis of a large cohort of HLA-identical sibling donor allogeneic stem cell transplant (allo-SCT) patients. A total of 25 SNPs in 12 cytokine genes were evaluated in 509 patients. Data were analyzed using a linear regression model and the least absolute shrinkage and selection operator (LASSO). The statistical model was constructed by randomly selecting 85% of cases (training set), and the predictive ability was confirmed based on the remaining 15% of cases (test set). Models including clinical and genetic variables (CG-M) predicted severe aGVHD significantly better than models including only clinical variables (C-M) or only genetic variables (G-M). For grades 3-4 aGVHD, the correct classification rates (CCR1) were: 100% for CG-M, 88% for G-M, and 50% for C-M. On the other hand, CG-M and G-M predicted extensive cGVHD better than C-M (CCR1: 80% vs. 66.7%, respectively). A risk score was calculated based on LASSO multivariate analyses. It was able to correctly stratify patients who developed grades 3-4 aGVHD (P < .001) and extensive cGVHD (P < .001). The novel predictive models proposed here improve the prediction of severe GVHD after allo-SCT. This approach could facilitate personalized risk-adapted clinical management of patients undergoing allo-SCT.